(*) CN Approval Date: 2022. 10.10
(*) USA Approval Date: 2019. 05.13.
1st Line Treat. with Sorafenib
2nd Line Treat. with RamuciruMAb
Advanced or Metastatic Cancer
Biomarker-Driven Therapy>Alpha-Feto
Company
Company Marketing CN
Generic Name
Patent>USA Patent Number
RTM
RTM Web-Site